Abnormal Expression of microRNA-296-3p in Type 2 Diabetes Patients and its Role in Pancreatic β-Cells Function by Targeting Tensin Homolog Deleted on Chromosome Ten

Cheng, Minggang; Guo, Yichen; Zhong, Weichuan; Chen, Xueyan; Guo, Guangzhou

doi:10.1007/s10528-021-10083-6

Cited by 3 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that miRNAs exert their functions by regulating the expression of their downstream target genes 18–20 . Studies have shown that miR‐296‐3p has multiple target genes such as E‐cadherin, 25 PTEN 27 and SOX4 44 . However, in this study, we did not analyse the target genes of miR‐296‐3p to clarify the regulatory mechanism of its role in pancreatic β‐cells.…”

Section: Discussionmentioning

confidence: 88%

“…25 A recent study showed that miR-296-3p is significantly downregulated in patients with type 2 diabetes and that it protects pancreatic β-cell against uric acid-induced dysfunction by targeting PTEN. 27 However, there are no reports regarding the potential role of miR-296-3p in GDM.…”

Section: Introductionmentioning

confidence: 99%

“…miR‐296‐3p has also been shown to be involved in the accumulation of extracellular matrix in mesangial cells in diabetic nephropathy 25 . A recent study showed that miR‐296‐3p is significantly downregulated in patients with type 2 diabetes and that it protects pancreatic β‐cell against uric acid‐induced dysfunction by targeting PTEN 27 . However, there are no reports regarding the potential role of miR‐296‐3p in GDM.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Role of lncRNA‐MEG8/miR‐296‐3p axis in gestational diabetes mellitus

et al. 2022

View full text Add to dashboard Cite

Aim Gestational diabetes mellitus (GDM) is the most common complication in pregnancy. This study aimed to investigate the potential mechanism and effects of long‐noncoding RNA maternally expressed 8 (lncRNA‐MEG8) in GDM. Methods Targeted interactions involving lncRNA‐MEG8 and miR‐296‐3p were initially predicted using starBase software and then confirmed using dual‐luciferase reporter gene analysis. The expression levels of lncRNA‐MEG8 and miR‐296‐3p in peripheral blood samples from patients with GDM were measured using reverse transcription‐quantitative polymerase chain reaction. Enzyme‐linked immunosorbent assay was used to evaluate the overall levels of insulin and insulin secretion. Additionally, MTT and flow cytometric methods were used to detect cell viability and apoptosis. Cell apoptosis‐associated proteins were determined by western blotting. Results Our results indicated that lncRNA‐MEG8 is a potential target of miR‐296‐3p. lncRNA‐MEG8 level was higher, whereas that of miR‐296‐3p was lower in patients with GDM than in healthy individuals. LncRNA‐MEG8‐siRNA promoted insulin content and secretion. Furthermore, MEG8‐siRNA increased cell viability and decreased apoptosis. However, these changes were reversed by an miR‐296‐3p inhibitor. Moreover, a miR‐296‐3p mimic had the same effect on INS‐1 cells as MEG8‐siRNA, as evidenced by enhanced insulin secretion, cell viability, and reduced apoptosis. Conclusion LncRNA‐MEG8‐siRNA promotes pancreatic β‐cell function by upregulating miR‐296‐3p.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of lncRNA‐MEG8/miR‐296‐3p axis in gestational diabetes mellitus

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Other interesting examples of anti-apoptotic miRNAs include miR-296-3p-whose expression is reduced in the serum of T2D, which protects against uric acid-induced apoptosis and beta-cell dysfunction by targeting Pten (69). miR-433, downregulated in the beta-cells treated with high glucose, also exerts a protective effect.…”

Section: Mirnas As Gatekeepers For Beta-cell Apoptosismentioning

confidence: 99%

miRNAs provide mechanisms for integrated control of endocrine pancreas homeostasis and metabolic disease pathogenesis: a narrative review

Du¹,

Vidal-Puig²,

Rodríguez‐Cuenca³

2022

ExRNA

View full text Add to dashboard Cite

Background and Objective: microRNAs (miRNAs) are short non-coding RNAs that have emerged to be the novel post-transcriptional regulators of gene expression, contributing to the development of metabolic diseases such as diabetes. Also, new and more precise high-throughput analytical tools have made it possible to study miRNAs' complex causative roles and targets. Here, we summarise the available evidence for the roles of miRNAs in the endocrine pancreas regulating fundamental cellular processes in beta-cells and the pathology of diabetes.Methods: We searched PubMed for research conducted and published before June 2022 using classical Boolean expressions. Only manuscripts written in English were considered.Key Content and Findings: Numerous miRNAs in the endocrine pancreas have been reported to regulate the fundamental cellular processes in beta-cells, such as proliferation, differentiation, apoptosis, and insulin biosynthesis and secretion by post-transcriptionally repressing their targets, as well as contributing to the pathology of diabetes. Also, many miRNAs, as molecular cargo of exosomes-mediate the crosstalk between the pancreas and other peripheral organs, unravelling new pathophysiological mechanisms related to the onset and worsening of diabetes.Conclusions: This review summarised the existing evidence of the complex network of miRNAs regulating the endocrine pancreas function and pathology of diabetes, providing the theoretical base for a future scientific study revealing the mechanism of diabetes and facilitating the discovery of new therapeutical targets in clinical practise.

show abstract